Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15635741 | 0.87 | KDM4E (0.63) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1397659 | 0.86 | KDM4E (0.63) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27711176 | 0.85 | ALDH1A1 (0.56) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3236365 | 0.83 | ALDH1A1 (0.58) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL496532 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL432775 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL432773 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5386530 | 0.81 | PLK1 (0.58) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17938290 | 0.81 | ALDH1A1 (0.63) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8432960 | 0.81 | MEN1 (0.56) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349949-A | N- substituted indole derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| EP-2205566-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009074749-A2 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-06-18 | — | — | WO | disclosed |
| EP-0459561-B1 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME (GB) | 1995-09-20 | — | — | EP | disclosed |
| US-5268378-A | Oxo group in 2 and 4 position | MERCK SHARP & DOHME, LIMITED (GB) | 1993-12-07 | — | — | US | disclosed |
| EP-0459561-A2 | Dioxo-tetrahydroquinoline derivatives | MERCK SHARP & DOHME LTD. (GB) | 1991-12-04 | — | — | EP | disclosed |
| US-4089078-A | Arylazopyrazolone dyes for polyester | AMERICAN COLOR & CHEMICAL CORPORATION (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | KDM4E 2520/4885ALDH1A1 380/4885MEN1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.